Bayer
Bayer Expands Oncology Pipeline with $1.3B Kumquat Deal
Bayer; Kumquat Biosciences; oncology pipeline; KRAS G12D inhibitor; FDA approval; cancer therapy; precision oncology; commercialization; milestone payments
Bayer-allied NextRNA Therapeutics winds down operations after missing a milestone in their collaboration
NextRNA Therapeutics; Bayer; lncRNA; long non-coding RNA; oncology; biotech wind-down; missed milestone; Massachusetts biotech; seed and Series A funding; Dana-Farber; Carl Novina; 2025 biotech shutdowns
Bayer Layoffs Top 12,000 with More Cuts Expected Amid Ongoing Restructuring
Bayer; layoffs; restructuring; cost-cutting; employee reductions; Bill Anderson; 2025; pharma industry
Bayer Extends CEO Bill Anderson’s Contract; Sarepta C-Suite Turmoil
Bill Anderson; Bayer; CEO contract extension; company transformation; restructuring; Sarepta; C-suite changes; pharma industry
Bayer’s Lynkuet (elinzanetant) Wins First-in-World Approval in UK, Challenging Astellas’ Hot Flash Drug
Bayer; elinzanetant; Lynkuet; menopause; hot flashes; vasomotor symptoms; Astellas; non-hormonal therapy; MHRA approval; UK first approval
Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move
BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry
Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey
cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine
Bayer Restructuring Cuts 2,000 Jobs, Thins Management Layers in 2025
Bayer; restructuring; job cuts; management layers; layoffs; Frankfurt plant closure; pharmaceutical industry
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Bayer Expects Pharma Sales Dip in 2025 Despite Upcoming Launches
Bayer, pharmaceutical sales, revenue decline, new drug launches, Xarelto patent expiration